Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected males or non-pregnant, non-breast-feeding females who are \>= 18 years of age;~* CD4+ T-lymphocyte count less than 250 per mm3;~* Successful response to HAART (defined as an HIV RNA viral load of \<50 copies per mL) for a minimum of one year preceding study enrollment.~Exclusion Criteria:~* Opportunistic infection within the 6 months prior to study enrollment~* Active tuberculosis or other mycobacterial infection~* Uncontrolled high blood pressure or congestive heart failure class III or IV~* Systemic glucocorticoid or immunomodulator therapy within 30 days of study entry~* Prior history of Kaposi's sarcoma~* Prior history of lymphoma~* Active substance abuse within the last 30 days~* Uncontrolled psychiatric disorders, including depression~* Abnormal or inadequate liver or renal function~* Inadequate bone marrow function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Dose Cohort 1: 50 mcg/kg/day of TXA127
- 2 (Type: EXPERIMENTAL): Drug Cohort 2: 100 mcg/kg/day TXA127
- 3 (Type: EXPERIMENTAL): Drug Cohort 3: 200 mcg/kg/day TXA127
- 4 (Type: EXPERIMENTAL): Drug Cohort 4: 300 mcg/kg/day TXA127
- 5 (Type: EXPERIMENTAL): Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.

Based on this trial design, predict the completion outcome and termination type (if applicable).